Preclamol and parkinsonian fluctuations.

abstract：OBJECTIVE:To determine if levetiracetam is efficacious in the treatment of essential tremor. METHODS:Fifteen patients (3 women), aged 35 to 83 years, with essential tremor were studied in a double-blind, placebo-controlled crossover trial of levetiracetam. During the 2 treatment periods, levetiracetam or placebo was t...

journal_title：Clinical neuropharmacology

authors： Elble RJ,Lyons KE,Pahwa R

更新日期：2007-11-01 00:00:00

abstract：:The authors compared the two portions of the OFF period in patients with Parkinson disease and response fluctuations: time to ON (the latency from levodopa intake to turning ON) and wearing off (time from termination of the beneficial dose effect until the time when the next dose was taken). Time to ON was more than t...

journal_title：Clinical neuropharmacology

authors： Merims D,Djaldetti R,Melamed E

更新日期：2003-07-01 00:00:00

abstract：:A matter of debate is the impact of levodopa (LD) application in patients with Parkinson disease (PD) on altered force development and coordination, which are also influenced by the strength of muscles used. The objectives were to compare the motor response, the development of grip strength, and the pharmacokinetic be...

journal_title：Clinical neuropharmacology

authors： Müller T,Kolf K,Ander L,Woitalla D,Muhlack S

更新日期：2008-05-01 00:00:00

abstract：OBJECTIVES:Aripiprazole and ziprasidone are 2 antipsychotic medications that are relatively devoid of the metabolic adverse effects associated with the second-generation antipsychotics. This study aimed to evaluate the effectiveness of switching to ziprasidone in patients who had insufficient response or intolerance to...

journal_title：Clinical neuropharmacology

authors： Kim SW,Shin IS,Kim JM,Bae KY,Yang SJ,Yoon JS

更新日期：2010-05-01 00:00:00

abstract：OBJECTIVES:To describe further the phenomenology of drug-induced psychosis (DIP) in patients with Parkinson disease (PD) and assess which items on two common psychosis rating instruments-the Brief Psychiatric Rating Scale (BPRS) and the Neuropsychiatric Inventory (NPI)-are the best measure of DIP by comparing them with...

journal_title：Clinical neuropharmacology

authors： Chou KL,Messing S,Oakes D,Feldman PD,Breier A,Friedman JH

更新日期：2005-09-01 00:00:00

abstract：OBJECTIVES:Obsessive-compulsive disorder (OCD) is notably a comorbid disorder in patients with schizophrenia. This study aimed to evaluate clinical features and correlates of early onset patients with schizophrenia with OCD. METHODS:In the present study, we included 10 patients with both schizophrenia and OCD and 19 p...

journal_title：Clinical neuropharmacology

authors： Baytunca B,Kalyoncu T,Ozel I,Erermiş S,Kayahan B,Öngur D

更新日期：2017-11-01 00:00:00

abstract：:This study was devised to check the feasibility and validity of a rating scale specifically designed to evaluate gait impairment in Parkinson's disease (RSGE). Demographic data, a brief questionnaire on general aspects influencing gait and mobility, a battery of scales (Barthel Index; Hoehn and Yahr staging; and North...

journal_title：Clinical neuropharmacology

authors： Martínez-Martín P,García Urra D,del Ser Quijano T,Balseiro Gómez J,Gómez Utrero E,Piñeiro R,Andrés MT

更新日期：1997-06-01 00:00:00

abstract：:Heart rate variability (HRV) reflects the cardiac autonomic regulation, and reduced HRV is considered a pathophysiological link between depression and cardiovascular mortality. So far, there is only limited information on the effects of venlafaxine and mirtazapine on HRV.We studied 28 nondepressed controls and 41 mode...

journal_title：Clinical neuropharmacology

authors： Terhardt J,Lederbogen F,Feuerhack A,Hamann-Weber B,Gilles M,Schilling C,Lecei O,Deuschle M

更新日期：2013-11-01 00:00:00

abstract：OBJECTIVES:Our study aimed to identify the association of norepinephrine transporter gene (SLC6A2), synaptosomal-associated protein of the 25-kDa gene (SNAP-25), and latrophilin 3 gene (LPHN3) with osmotic-controlled release oral delivery system methylphenidate (OROS MPH) treatment response. METHODS:One hundred thirty...

journal_title：Clinical neuropharmacology

authors： Song J,Kim SW,Hong HJ,Lee MG,Lee BW,Choi TK,Lee SH,Yook KH

更新日期：2014-09-01 00:00:00

abstract：:Seven of 63 children (11%) treated with clobazam (CLB) for refractory epilepsy developed a severe behavior disorder. This disorder was characterized by aggressive agitation, self injurious behavior, insomnia, and incessant motor activity occurring between 10 and 55 days after initiation of drug therapy. The affected c...

journal_title：Clinical neuropharmacology

authors： Sheth RD,Goulden KJ,Ronen GM

更新日期：1994-08-01 00:00:00

abstract：OBJECTIVE:We present 3 new cases of psychotic symptoms in patients with adult attention-deficit/hyperactivity disorder while regularly treated with a stimulant therapy with methylphenidate. METHODS:Existing literature about this theme is reviewed, and potential mechanisms are discussed. RESULTS AND CONCLUSIONS:Medica...

journal_title：Clinical neuropharmacology

authors： Kraemer M,Uekermann J,Wiltfang J,Kis B

更新日期：2010-07-01 00:00:00

abstract：:The description of multiple classes of opioid receptors has had a major impact on our understanding of the mechanisms of analgesia. Three major classes of opioid receptors have been defined: mu, kappa, and delta. The mu receptors have been further subclassified into two distinct subtypes (mu 1 and mu 2), as have the d...

journal_title：Clinical neuropharmacology

authors： Pasternak GW

更新日期：1993-02-01 00:00:00

abstract：:The purpose of this study was to evaluate the effect of amantadine sulfate infusion on the N30 component of the median nerve short-latency somatosensory evoked potentials (SSEPs) in patients with Parkinson's disease (PD). Twenty patients with advanced PD and severe motor fluctuations received a 6-day course of amantad...

journal_title：Clinical neuropharmacology

authors： Bostantjopoulou S,Katsarou Z,Georgiadis G,Zafiriou D,Kazis A

更新日期：2002-03-01 00:00:00

abstract：:A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia. No risk factors for rhabdomyolysis were found, but the calcium-dependent potassium efflux, normally responsible for membrane hyperpolarization and muscle refractoriness, was severely ...

journal_title：Clinical neuropharmacology

authors： Koren W,Koren E,Nacasch N,Ehrenfeld M,Gur H

更新日期：1998-07-01 00:00:00

abstract：:In recent studies, disorders of chromatic and achromatic vision in parkinsonian patients have been demonstrated; these could be partially restored after application of L-Dopa. In this study, the effect of a 3-day infusion therapy with amantadine sulphate on color vision was evaluated in 19 parkinsonian patients by use...

journal_title：Clinical neuropharmacology

authors： Büttner T,Kuhn W,Müller T,Patzold T,Przuntek H

更新日期：1995-10-01 00:00:00

abstract：:The long-term effects of mesulergine, a new drug with dopamine agonistic properties, were studied in 28 patients with Parkinson's disease. In 18 patients with late side effects of levodopa, the addition of mesulergine (10.9 mg/day) induced significant decreases in the global (-48%), rigidity (-62%), and akinesia (-37%...

journal_title：Clinical neuropharmacology

authors： Rascol A,Montastruc JL,Rascol O,Senard JM

更新日期：1986-01-01 00:00:00

abstract：:Prion diseases are invariably fatal. Recently, quinacrine and chlorpromazine have been suggested as immediate candidates for the treatment of Creutzfeldt-Jakob disease and other prion diseases. The objective of this paper was to report on 2 fatal familial insomnia patients whose overall condition worsened despite quin...

journal_title：Clinical neuropharmacology

authors： Benito-León J

更新日期：2004-07-01 00:00:00

abstract：:The effects of carbamazepine (CBZ) on spontaneous secretion of prolactin (PRL) and after stimulation with thyrotropin releasing hormone (TRH) were evaluated. Volunteer subjects after acute CBZ administration, and epileptic subjects with complex partial seizures chronically treated with CBZ, were examined. In an epilep...

journal_title：Clinical neuropharmacology

authors： Bonuccelli U,Murialdo G,Martino E,Lecchini S,Bonura ML,Bambini G,Murri L

更新日期：1985-01-01 00:00:00

abstract：OBJECTIVE:Multiple sclerosis (MS) is a degenerative neurological condition that results in impairments in multiple domains including cognition, fatigue, and mood. Dalfampridine-extended release (D-ER) has been approved to improve walking in persons with MS. It is plausible that D-ER could improve cognition, fatigue, an...

journal_title：Clinical neuropharmacology

authors： Triche EW,Ruiz JA,Olson KM,Lo AC

更新日期：2016-03-01 00:00:00

abstract：:The present study was carried out in order to verify whether, in benzodiazepine-medicated healthy volunteers, oxiracetam retained the properties already observed after administration in normal volunteers. In a cross-over study, 12 volunteers, medicated the night before with 5 mg diazepam, were i.v. treated with 1 g ox...

journal_title：Clinical neuropharmacology

authors： Giaquinto S,Nolfe G,Vitali S

更新日期：1986-01-01 00:00:00

abstract：:The primary objective of this study was to describe the pharmacokinetics of oral pergolide in patients with mild to moderate Parkinson disease using a new high-performance liquid chromatography-tandem mass spectrometry assay. A secondary objective was to investigate the relationship between plasma concentrations and e...

journal_title：Clinical neuropharmacology

authors： Thalamas C,Rajman I,Kulisevsky J,Lledó A,Mackie AE,Blin O,Gillespie TA,Seger M,Rascol O

更新日期：2005-05-01 00:00:00

abstract：:The effect of bromocriptine at doses up to 20 mg/day was studied in a single-blind format with a placebo phase in 15 Parkinson's disease patients with mild-to-moderate disability who had not been previously treated with levodopa. For the 11 patients who completed the 9 month trial, both Northwestern University Disabil...

journal_title：Clinical neuropharmacology

authors： Tolosa E,Blesa R,Bayes A,Forcadell F

更新日期：1987-04-01 00:00:00

abstract：:The treatment of obesity remains a puzzling challenge because long-term maintenance of weight loss--one of the most suitable goals--is rarely achieved with conventional methods. Among the theoretical measures able to maintain a permanent and bearable constraint to obtain the maintenance of weight loss is long-term (li...

journal_title：Clinical neuropharmacology

authors： Guy-Grand BJ

更新日期：1988-01-01 00:00:00

abstract：:In nine patients with orthostatic hypotension due to multiple system atrophy, the effects of octreotide (100 micrograms s.c.), a somatostatin analogue, on blood pressure (BP), heart rate (HR), and norepinephrine (NE) plasma levels after 60 degrees head up tilt test were evaluated by a randomly controlled study. Octreo...

journal_title：Clinical neuropharmacology

authors： Bordet R,Benhadjali J,Destée A,Belabbas A,Libersa C

更新日期：1995-02-01 00:00:00

abstract：:Interferon (IFN) is the most widely prescribed drug of choice for chronic hepatitis B infection, which is a common health problem in our country. Therapy with IFN-alpha may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, seizure, and depressive disorders. In this case report,...

journal_title：Clinical neuropharmacology

authors： Atasoy N,Ustundag Y,Konuk N,Atik L

更新日期：2004-05-01 00:00:00

abstract：OBJECTIVES:Autism spectrum disorders (ASDs) have core impairments in social communication as well as the presence of repetitive, stereotypic behaviors and restricted interests. Older adolescents and young adults are particularly impacted by these deficits. Preclinical data implicate glutamatergic dysfunction in the pat...

journal_title：Clinical neuropharmacology

authors： Urbano M,Okwara L,Manser P,Hartmann K,Herndon A,Deutsch SI

更新日期：2014-05-01 00:00:00

abstract：:Therapeutic strategies in the treatment of dystonia consist primarily of pharmacologic, surgical, and supportive approaches. Many recent advances have been made in the treatment of dystonia with newer medications, availability of different botulinum toxins, and surgical procedures. However, these treatment modalities ...

journal_title：Clinical neuropharmacology

authors： Goldman JG,Comella CL

更新日期：2003-03-01 00:00:00

abstract：OBJECTIVES:The units of different botulinum toxin products are not identical, and the dose equivalence has been debated for several years. In the year 2000, our clinic changed the recommended botulinum toxin product from Botox to Dysport for the treatment of cervical dystonia. Based on published reports, where dose con...

journal_title：Clinical neuropharmacology

authors： Rystedt A,Nyholm D,Naver H

更新日期：2012-11-01 00:00:00

abstract：:A large number of patients with neurosyphilis present dementia with a progressive course and psychiatric symptoms such as depression, mania, and psychosis. Despite prompt and proper antibiotic treatment, the recovery is often incomplete, especially when tissue damage has occurred. We reported a patient with persisted ...

journal_title：Clinical neuropharmacology

authors： Wu YS,Lane HY,Lin CH

更新日期：2015-07-01 00:00:00

abstract：:Forty patients with different clinical and electrophysiological types of myoclonus were treated with piracetam (18-24 g per day, p.o.) alone, or with other drugs (clonazepam, sodium valproate, and primidone) in different combinations. Piracetam in monotherapy improved the electrophysiological abnormalities in patients...

journal_title：Clinical neuropharmacology

authors： Obeso JA,Artieda J,Quinn N,Rothwell JC,Luquin MR,Vaamonde J,Marsden CD

更新日期：1988-12-01 00:00:00